The new R&D and manufacturing facilities powering our US growth - Merck | Home
The new R&D and manufacturing facilities powering our US growth Merck | Home
Merck & Co Company News
Merck & Co., Inc. $MRK Stock: Willis Investment Counsel Cuts Holdings - MarketBeat
Merck & Co., Inc. $MRK Stock: Willis Investment Counsel Cuts Holdings MarketBeat
Merck & Co Inc Stock (MRK) Opened Up by 3.79% on Oct 20: What Signal Does It Send? - TradingKey
Merck & Co Inc Stock (MRK) Opened Up by 3.79% on Oct 20: What Signal Does It Send? TradingKey
64,996 Merck & Co., Inc. $MRK Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat
64,996 Merck & Co., Inc. $MRK Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd MarketBeat
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors - Business Wire
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors Business Wire
Merck & Co.’s Mission to Manufacture for Life - VEDP
Merck & Co.’s Mission to Manufacture for Life VEDP
Merck & Co. stock: Goldman Sachs cuts target for Merck & Co. stock to USD 155.00 - ad-hoc-news.de
Merck & Co. stock: Goldman Sachs cuts target for Merck & Co. stock to USD 155.00 ad-hoc-news.de
Our Q2 2026 financial results - Merck | Home
Our Q2 2026 financial results Merck | Home
13,487 Merck & Co., Inc. $MRK Shares Sold by Generali Investments Management Co LLC - MarketBeat
13,487 Merck & Co., Inc. $MRK Shares Sold by Generali Investments Management Co LLC MarketBeat
Merck & Co., Inc. $MRK Position Boosted by Fairvoy Private Wealth LLC - MarketBeat
Merck & Co., Inc. $MRK Position Boosted by Fairvoy Private Wealth LLC MarketBeat
Merck & Co., Inc. $MRK Stock: 1834 Investment Advisors Co. Decreases Position - MarketBeat
Merck & Co., Inc. $MRK Stock: 1834 Investment Advisors Co. Decreases Position MarketBeat
Merck & Co., Inc. $MRK Stock: Birch Hill Investment Advisors LLC Cuts Holdings - MarketBeat
Merck & Co., Inc. $MRK Stock: Birch Hill Investment Advisors LLC Cuts Holdings MarketBeat
Merck & Co., Inc. $MRK Stock: Hengehold Capital Management LLC Reduces Position - MarketBeat
Merck & Co., Inc. $MRK Stock: Hengehold Capital Management LLC Reduces Position MarketBeat
Merck & Co., Inc. $MRK Stock: Banque Pictet & Cie SA Cuts Holdings - MarketBeat
Merck & Co., Inc. $MRK Stock: Banque Pictet & Cie SA Cuts Holdings MarketBeat
Merck & Co., Inc. $MRK Stock: State of Alaska Department of Revenue Reduces Stake - MarketBeat
Merck & Co., Inc. $MRK Stock: State of Alaska Department of Revenue Reduces Stake MarketBeat
Milestone Asset Management LLC Sells 9,248 Shares of Merck & Co., Inc. $MRK - MarketBeat
Milestone Asset Management LLC Sells 9,248 Shares of Merck & Co., Inc. $MRK MarketBeat
Curated Wealth Partners LLC Sells 127,541 Shares of Merck & Co., Inc. $MRK - MarketBeat
Curated Wealth Partners LLC Sells 127,541 Shares of Merck & Co., Inc. $MRK MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Godsey & Gibb Inc. - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Godsey & Gibb Inc. MarketBeat
1,133,024 Merck & Co., Inc. $MRK Shares Sold by Assenagon Asset Management S.A. - MarketBeat
1,133,024 Merck & Co., Inc. $MRK Shares Sold by Assenagon Asset Management S.A. MarketBeat
Merck & Co., Inc. $MRK Stock: Fort Washington Investment Advisors Inc. OH Decreases Holdings - MarketBeat
Merck & Co., Inc. $MRK Stock: Fort Washington Investment Advisors Inc. OH Decreases Holdings MarketBeat
Nimbus hires Merck & Co dealmaker as chief business officer - The Pharma Letter
Nimbus hires Merck & Co dealmaker as chief business officer The Pharma Letter
Merck & Co’s US antibiotic withdrawal sends the wrong signals for combating resistance - Chemistry World
Merck & Co’s US antibiotic withdrawal sends the wrong signals for combating resistance Chemistry World
Merck & Co., Inc. $MRK Stock: Cliftonlarsonallen Wealth Advisors LLC Cuts Holdings - MarketBeat
Merck & Co., Inc. $MRK Stock: Cliftonlarsonallen Wealth Advisors LLC Cuts Holdings MarketBeat
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor - Business Wire
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor Business Wire
Merck & Co. stock costs EUR 129.19 before October 29 results - ad-hoc-news.de
Merck & Co. stock costs EUR 129.19 before October 29 results ad-hoc-news.de
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline - Business Wire
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline Business Wire
Merck & Co Inc Stock (MRK) Moved Up by 3.73% on Oct 14: A Full Analysis - TradingKey
Merck & Co Inc Stock (MRK) Moved Up by 3.73% on Oct 14: A Full Analysis TradingKey
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 - Business Wire
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 Business Wire
Merck is pharma’s most patent-exposed company. Now it’s reinventing itself. - Pharma Voice
Merck is pharma’s most patent-exposed company. Now it’s reinventing itself. Pharma Voice
Merck posts better-than-expected second-quarter results on Keytruda strength - Reuters
Merck posts better-than-expected second-quarter results on Keytruda strength Reuters
Merck eyes expansion of Montgomery County campus amid $2.9B investment - The Business Journals
Merck eyes expansion of Montgomery County campus amid $2.9B investment The Business Journals
Merck's drug for diabetes-related eye disease meets trial goal - Reuters
Merck's drug for diabetes-related eye disease meets trial goal Reuters
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline - CNBC
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline CNBC
Our Q4 and full-year 2025 financial results - Merck | Home
Our Q4 and full-year 2025 financial results Merck | Home
Merck's 2026 outlook clouds upbeat fourth-quarter results - Reuters
Merck's 2026 outlook clouds upbeat fourth-quarter results Reuters
Merck trims another 54 jobs in New Jersey amid multiyear cost-cutting initiative - Fierce Pharma
Merck trims another 54 jobs in New Jersey amid multiyear cost-cutting initiative Fierce Pharma
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC - BioPharma Dive
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC BioPharma Dive
StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too - Genetic Engineering and Biotechnology News
StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too Genetic Engineering and Biotechnology News
Merck, Daiichi pull US application for second partnered cancer therapy - Reuters
Merck, Daiichi pull US application for second partnered cancer therapy Reuters
FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) - Merck | Home
FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) Merck | Home